Express Scripts excluded Teva's migraine drug from coverage
Drugmaker Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is lower today, down 4.7% to trade at $21.24, amid reports that Express Scripts (ESRX) excluded Teva's migraine drug from coverage. In addition to the drop today, TEVA recently flashed a bearish signal, indicating the slide may be far from over.
Teva stock, for the second time within a month, is within one standard deviation of its 40-day moving average, after a lengthy stretch below this trendline. In the past three years, there have been 11 other signals of this kind, after which Teva shares were down by an average of 4.8% a month later, and positive only 27% of the time, per data from Schaeffer's Senior Quantitative Analyst Rocky White.
TEVA's drop today likely snaps a three-day winning streak. Another 4.8% drop in the next month would have the stock breaching the $21 level, which has recently emerged as support the last two months.
There is ample room aboard the bearish bandwagon in the event of a TEVA downturn. Short interest fell by 11% in the most recent reporting period, to 31.8 million shares -- the lowest since July 2017.
The good news for options traders is that TEVA sports a Schaeffer's Volatility Scorecard (SVS) of 93 out of 100, which shows the stock has tended to make larger-than-expected moves on the charts compared to what the options market had priced in. In simpler terms, it may be an opportune time to speculate with Teva options.